Loading…
Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome. It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-122M | $-3M | $-116M | 2.8% | - | - |
| 2024 | $0M | $-155M | $-157M | $-149M | 85.9% | - | - |
| 2023 | $0M | $-143M | $-118M | $74M | 471.6% | - | -348.5% |
| 2022 | $0M | $-158M | $47M | $-87M | 55.3% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Cost Of Revenue | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 |
| Operating Expense | 163.39 | 164.53 | 166.95 | 122.80 |
| Operating Income | -163.39 | -164.53 | -166.95 | -122.80 |
| EBITDA | -158.38 | -143.16 | -154.70 | -121.83 |
| EBIT | -159.33 | -144.08 | -155.65 | -122.80 |
| Pretax Income | -182.03 | -174.92 | -180.32 | -2.80 |
| Tax Provision | 0 | 0 | 2.31 | 2.01 |
| Net Income | 47.42 | -117.81 | -156.81 | -3.35 |
| Net Income Common Stockholders | 47.42 | -117.81 | -156.81 | -3.35 |
| Total Expenses | 163.39 | 164.53 | 166.95 | 122.80 |
| Interest Expense | 22.70 | 30.84 | 24.68 | 0 |
| Interest Income | 4.06 | 16.34 | 11.29 | 5.06 |
| Research And Development | 112.72 | 114.87 | 119.52 | 81.30 |
| Selling General And Administration | 50.67 | 49.66 | 47.43 | 41.50 |
| Normalized EBITDA | -158.38 | -147.27 | -154.72 | -236.78 |
| Normalized Income | -182.03 | -179.03 | -182.64 | -95.61 |
| Basic EPS | 0.76 | -1.88 | -2.70 | -0.05 |
| Diluted EPS | 0.76 | -1.88 | -2.70 | -0.05 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 24.14 |
| Tax Rate For Calcs | 0 | 0 | 0.21 | 0.21 |
| Total Unusual Items | 0 | 4.11 | 0.02 | 114.94 |
| Total Unusual Items Excluding Goodwill | 0 | 4.11 | 0.02 | 114.94 |
| Net Income From Continuing Operation Net Minority Interest | -182.03 | -174.92 | -182.63 | -4.81 |
| Reconciled Depreciation | 0.95 | 0.92 | 0.95 | 0.96 |
| Reconciled Cost Of Revenue | 0 | 0 | 0 | 0 |
| Net Interest Income | -18.64 | -14.50 | -13.39 | 5.06 |
| Net Income From Continuing And Discontinued Operation | 47.42 | -117.81 | -156.81 | -3.35 |
| Total Operating Income As Reported | -163.39 | -164.53 | -166.95 | -122.80 |
| Diluted Average Shares | 62.74 | 62.74 | 58.17 | 63.51 |
| Basic Average Shares | 62.74 | 62.74 | 58.17 | 63.51 |
| Diluted NI Availto Com Stockholders | 47.42 | -117.81 | -156.81 | -3.35 |
| Net Income Including Noncontrolling Interests | 47.42 | -117.81 | -156.81 | -3.35 |
| Net Income Discontinuous Operations | 229.45 | 57.11 | 25.81 | 1.46 |
| Net Income Continuous Operations | -182.03 | -174.92 | -182.63 | -4.81 |
| Other Income Expense | 0 | 4.11 | 0.02 | 114.94 |
| Other Non Operating Income Expenses | 0 | 0 | 0 | 0 |
| Special Income Charges | 0 | 4.11 | 0 | 251.66 |
| Gain On Sale Of Business | 0 | 0 | 0 | 237.59 |
| Other Special Charges | 0 | -4.11 | 0 | -14.07 |
| Gain On Sale Of Security | 0 | 0 | 0.02 | -136.72 |
| Net Non Operating Interest Income Expense | -18.64 | -14.50 | -13.39 | 5.06 |
| Interest Expense Non Operating | 22.70 | 30.84 | 24.68 | 0 |
| Interest Income Non Operating | 4.06 | 16.34 | 11.29 | 5.06 |
| General And Administrative Expense | 50.67 | 49.66 | 47.43 | 41.50 |
| Other Gand A | 42.63 | 42.52 | 41.07 | 36.84 |
| Salaries And Wages | 8.04 | 7.14 | 6.36 | 4.66 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Omeros Corporationthis co. | OMER | $1.0B | - | -8.61 | 2.8% | -9.24 |
| CareDx, Inc. | CDNA | $1.1B | - | 3.49 | -7.0% | -124.58 |
| Teladoc Health, Inc. | TDOC | $1.1B | - | 0.77 | -14.5% | 39.94 |
| IRADIMED CORPORATION | IRMD | $1.1B | 47.83 | 11.31 | 23.8% | 37.30 |
| The Pennant Group, Inc. | PNTG | $1.1B | 36.56 | 3.22 |
| 7.9% |
| 25.85 |
| Septerna, Inc. | SEPN | $1.1B | - | 2.75 | -12.8% | -8.66 |
| Xeris Biopharma Holdings, Inc. | XERS | $1.0B | - | 73.41 | 4.0% | 31.98 |
| Aktis Oncology, Inc. | AKTS | $1.0B | - | -0.12 | 43.6% | -15.93 |
| Collegium Pharmaceutical, Inc. | COLL | $1.0B | 16.75 | 3.49 | 20.8% | 4.08 |
| Peer Median | - | 36.56 | 3.36 | 6.0% | 14.96 | |